Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia

• Status: Not yet recruiting
• Trial end date: 2020-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Methods: Single-center pilot study included PCR+ SARS-CoV2-patients, hospitalized from April to May 2020 in Puebla, Mexico. Comparative treatment with steroids plus CsA or steroids. Mild, moderate or severe pneumonia was measured by clinical, laboratory tests, lung damage score by computed tomography, and score for clinical improvement. Death rate was evaluated at 28 days.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Confirmed COVID 19 pneumonia by clinical, lung computed Tomography and RT-PCR nasopharyngeal swabs.

Exclusion Criteria:

• Influenza infection.